Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Zhang J, Zhu S, Ma N, Johnston LJ, Wu C, Ma X
Always follow the advice of your medical professional
Sustainable Habits for a Lifetime: Ultimately, GLP-1 is a tool in your toolbox, but sustainable habits are the foundation of lasting wellness
The US Food and Drug Administration and the European Medicines Agency have required safety studies of these drugs on cardiovascular risk in patients with diabetes, which have allowed us to know their cardiovascular effects, including stroke, and further our understanding of its benefits in patients with type 2 diabetes and high vascular risk
Folgt aus der antioxidativen Wirkung von GHK-Cu auf melanogene Prozesse